1C80 Stock Overview
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Vyant Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.23 |
| 52 Week High | US$3.80 |
| 52 Week Low | US$0.21 |
| Beta | 0.55 |
| 11 Month Change | 0% |
| 3 Month Change | 11.54% |
| 1 Year Change | -93.97% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 1C80 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -94.0% | -17.2% | 8.2% |
Return vs Industry: 1C80 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 1C80 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 1C80 volatility | |
|---|---|
| 1C80 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 1C80's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 1C80's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 4 | Andy LaFrence | www.vyantbio.com |
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson’s disease (PD).
Vyant Bio, Inc. Fundamentals Summary
| 1C80 fundamental statistics | |
|---|---|
| Market cap | €977.64k |
| Earnings (TTM) | -€11.98m |
| Revenue (TTM) | €365.04k |
2.7x
P/S Ratio-0.1x
P/E RatioIs 1C80 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1C80 income statement (TTM) | |
|---|---|
| Revenue | US$397.00k |
| Cost of Revenue | US$736.00k |
| Gross Profit | -US$339.00k |
| Other Expenses | US$12.69m |
| Earnings | -US$13.03m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.06 |
| Gross Margin | -85.39% |
| Net Profit Margin | -3,281.86% |
| Debt/Equity Ratio | 1.3% |
How did 1C80 perform over the long term?
See historical performance and comparison